Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses
暂无分享,去创建一个
J. Casanova | P. Itin | J. Uitto | G. Orth | E. Jouanguy | S. J. de Jong | E. Imahorn | B. Burger
[1] X. Mo,et al. A novel homozygous DOCK8 mutation associated with unusual coexistence of gross molluscum contagiosum and epidermodysplasia verruciformis in a DOCK8 deficiency patient , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[2] P. Itin,et al. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] R. Hoyos-Bachiloglu,et al. Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. , 2017, Clinical immunology.
[4] B. Amin,et al. Acquired Epidermodysplasia Verruciformis and Its Relationship to Immunosuppressive Therapy: Report of a Case and Review of the Literature. , 2017, Journal of drugs in dermatology : JDD.
[5] C. Ma,et al. Identification of LCK mutation in a family with atypical epidermodysplasia verruciformis with T‐cell defects and virus‐induced squamous cell carcinoma , 2016, The British journal of dermatology.
[6] H. Shimizu,et al. Genetic analysis of a novel splice‐site mutation in TMC8 reveals the in vivo importance of the transmembrane channel‐like domain of TMC8 , 2016, The British journal of dermatology.
[7] J. Casanova. Severe infectious diseases of childhood as monogenic inborn errors of immunity , 2015, Proceedings of the National Academy of Sciences.
[8] P. Howley,et al. Beta genus papillomaviruses and skin cancer. , 2015, Virology.
[9] S. Tyring,et al. Deleterious Effect of Radiation Therapy on Epidermodysplasia Verruciformis Patients , 2015, Journal of cutaneous medicine and surgery.
[10] T. Brümmendorf,et al. Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency. , 2015, Blood.
[11] J. Bouwes Bavinck,et al. Characterization of skin lesions induced by skin‐tropic α‐ and β‐papillomaviruses in a patient with epidermodysplasia verruciformis , 2014, The British journal of dermatology.
[12] J. Lupski,et al. Compound Heterozygous CORO1A Mutations in Siblings with a Mucocutaneous-Immunodeficiency Syndrome of Epidermodysplasia Verruciformis-HPV, Molluscum Contagiosum and Granulomatous Tuberculoid Leprosy , 2014, Journal of Clinical Immunology.
[13] R. Badolato,et al. α- and β-papillomavirus infection in a young patient with an unclassified primary T-cell immunodeficiency and multiple mucosal and cutaneous lesions. , 2014, Journal of the American Academy of Dermatology.
[14] V. Sondak,et al. Case–control study of genus‐beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma , 2014, International journal of cancer.
[15] Mona Safizadeh,et al. Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis. , 2014, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[16] H. Pfister,et al. Human papillomavirus and immunosuppression. , 2014, Current problems in dermatology.
[17] G. Gaud,et al. Loss of the HPV-Infection Resistance EVER2 Protein Impairs NF-κB Signaling Pathways in Keratinocytes , 2014, PloS one.
[18] D. Linder,et al. Acquired Epidermodysplasia Verruciformis: A Comprehensive Review and a Proposal for Treatment , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[19] L. Naldi,et al. Human Papillomavirus Load in Eyebrow Hair Follicles and Risk of Cutaneous Squamous Cell Carcinoma , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[20] Y. Jacob,et al. EVER2 protein binds TRADD to promote TNF-α-induced apoptosis , 2013, Cell Death and Disease.
[21] David A. Williams,et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. , 2012, The Journal of clinical investigation.
[22] A. Fischer,et al. Inherited MST1 Deficiency Underlies Susceptibility to EV-HPV Infections , 2012, PloS one.
[23] J. Casanova,et al. EVER2 Deficiency is Associated with Mild T-cell Abnormalities , 2012, Journal of Clinical Immunology.
[24] L. Dupré,et al. EVER Proteins, Key Elements of the Natural Anti-Human Papillomavirus Barrier, Are Regulated upon T-Cell Activation , 2012, PloS one.
[25] O. Sanal,et al. Additional Diverse Findings Expand the Clinical Presentation of DOCK8 Deficiency , 2012, Journal of Clinical Immunology.
[26] S. Landolfo,et al. Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. , 2012, The Journal of investigative dermatology.
[27] P. Itin,et al. Homozygosity for the c.917A → T (p.N306l) Polymorphism in the EVER2/TMC8 Gene of Two Sisters with Epidermodysplasia Verruciformis Lewandowsky-Lutz Originally Described by Wilhelm Lutz , 2010, Dermatology.
[28] M. Pawlita,et al. Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. , 2010, The Journal of investigative dermatology.
[29] Y. Jacob,et al. The EVER Proteins as a Natural Barrier against Papillomaviruses: a New Insight into the Pathogenesis of Human Papillomavirus Infections , 2009, Microbiology and Molecular Biology Reviews.
[30] K. Straif,et al. A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.
[31] T. Mitsuishi,et al. Epidermodysplasia verruciformis with keratoacanthoma, Bowen's disease and squamous cell carcinoma: isolation of high‐risk types of HPV 5 and unknown type of human papillomavirus , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.
[32] Y. Jacob,et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses , 2007, The Journal of experimental medicine.
[33] G. Orth. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. , 2006, Seminars in immunology.
[34] D. Ma,et al. Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. , 2006, Journal of dermatological science.
[35] Y. Jacob,et al. Cottontail Rabbit Papillomavirus E8 Protein Is Essential for Wart Formation and Provides New Insights into Viral Pathogenesis , 2006, Journal of Virology.
[36] B. Akgül,et al. HPV‐associated skin disease , 2006, The Journal of pathology.
[37] U. Dianzani,et al. CD8+ T-cell lymphocytopenia and lack of EVER mutations in a patient with clinically and virologically typical epidermodysplasia verruciformis. , 2005, Archives of dermatology.
[38] Xuejun Zhang,et al. Two frameshift mutations in the RNA-specific adenosine deaminase gene associated with dyschromatosis symmetrica hereditaria. , 2005, Archives of dermatology.
[39] A. Fischer,et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency , 2004, The Lancet.
[40] T. Kupper,et al. Immune surveillance in the skin: mechanisms and clinical consequences , 2004, Nature Reviews Immunology.
[41] A. Griffith,et al. Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. , 2003, Genomics.
[42] B. Hansson,et al. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. , 2003, The Journal of general virology.
[43] C. Festa Neto,et al. Clinical aspects of epidermodysplasia verruciformis , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.
[44] S. Heller,et al. TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins , 2003, BMC Genomics.
[45] B. Hansson,et al. General Acquisition of Human Papillomavirus Infections of Skin Occurs in Early Infancy , 2003, Journal of Clinical Microbiology.
[46] R. Geha,et al. Primary immunodeficiency diseases: an update , 2003, Clinical and experimental immunology.
[47] N. Ramoz,et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis , 2002, Nature Genetics.
[48] N. Christensen,et al. Intracutaneous DNA Vaccination with the E8 Gene of Cottontail Rabbit Papillomavirus Induces Protective Immunity against Virus Challenge in Rabbits , 2002, Journal of Virology.
[49] N. Ramoz,et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. , 2000, The Journal of investigative dermatology.
[50] Mulder,et al. Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals , 1999, The British journal of dermatology.
[51] N. Ramoz,et al. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. , 1999, The Journal of investigative dermatology.
[52] S. Jabłońska,et al. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. , 1997, Cancer research.
[53] G. Orth,et al. Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression. , 1997, Clinics in dermatology.
[54] S. Jabłońska,et al. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancers: the role of local immunosurveillance. , 1992, The American journal of the medical sciences.
[55] D. Lowy,et al. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. , 1990, The Journal of investigative dermatology.
[56] G. Orth,et al. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. , 1986, Journal of the American Academy of Dermatology.
[57] M. Yaniv,et al. Genomic structure of the cottontail rabbit (Shope) papillomavirus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[58] E. Chen,et al. Comparative analysis of the human type 1a and bovine type 1 papillomavirus genomes , 1983, Journal of virology.
[59] G. Orth,et al. Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. , 1979, Cancer research.
[60] G. Orth,et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[61] F. Pass,et al. Depressed immune function in epidermodysplasia verruciformis. , 1977, Archives of dermatology.
[62] S. Jablonska,et al. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. , 1972, Cancer research.
[63] M. Ruiter,et al. Demonstration by electronmicroscopy of an intranuclear virus in epidermodysplasia verruciformis. , 1966, The Journal of investigative dermatology.
[64] S. Jabłońska,et al. Zur Kenntnis der Epidermodysplasia verruciformis Lewandowsky-Lutz , 1957 .
[65] L. Forman. Inherited abnormalities of the skin and its appendages , 1934 .
[66] F. Lewandowsky,et al. Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis) , 1922, Archiv für Dermatologie und Syphilis.
[67] R. Geha,et al. Epidermodysplasia verruciformis as a manifestation of ARTEMIS deficiency in a young adult. , 2017, The Journal of allergy and clinical immunology.
[68] B. Burger,et al. Epidermodysplasia verruciformis. , 2014, Current problems in dermatology.
[69] G. Orth. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. , 2008, Current topics in microbiology and immunology.
[70] J. Casanova,et al. The human model: a genetic dissection of immunity to infection in natural conditions , 2004, Nature Reviews Immunology.
[71] Z. H. Hafeez,et al. Epidermodysplasia verruciformis. , 1996, JPMA. The Journal of the Pakistan Medical Association.
[72] G. Orth. Epidermodysplasia verruciformis: a model for understanding the oncogenicity of human papillomaviruses. , 1986, Ciba Foundation symposium.
[73] G. Orth,et al. T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. , 1981, Dermatologica.
[74] G. Orth,et al. Twenty-one years of follow-up studies of familial epidermodysplasia verruciformis. , 1979, Dermatologica.
[75] M. Lutzner. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. , 1978, Bulletin du cancer.
[76] Lutzner Ma. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. , 1978 .
[77] S. Jabłońska,et al. Cell-mediated immunity in epidermodysplasia verruciformis. , 1976, Dermatologica.
[78] K. K. Tan,et al. Familial epidermodysplasia verruciformis of Lewandowsky and Lutz. , 1972, Archives of dermatology.
[79] W. Biczysko,et al. On the viral etiology of epidermodysplasia verruciformis Lewandowsky-Lutz. Electron microscope studies. , 1968, Dermatologica.
[80] S. Jablonska,et al. On the viral etiology of epidermodysplasia verruciformis. , 1966, Dermatologica.
[81] W. Lutz. A propos de l’Epidermodysplasie verruciforme , 1946 .